These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26722766)

  • 81. Editorial comment on 'Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials'.
    Gnant M
    Eur J Cancer; 2016 May; 59():125-127. PubMed ID: 27033259
    [No Abstract]   [Full Text] [Related]  

  • 82. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.
    Yazici O; Aksoy S; Ucar O; Ozdemir N; Demir M; Sendur MA; Arik Z; Yaman S; Eren T; Uncu D; Zengin N
    Med Oncol; 2013; 30(3):609. PubMed ID: 23690271
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [A survey of the dosage of zoledronic acid and investigation of the relationship between renal function and adverse events].
    Yanae M; Nakao M; Fujiwara K; Kawaguchi A; Tsubaki M; Chiba Y; Morita T; Yamazoe Y; Nishida S
    Gan To Kagaku Ryoho; 2012 Jul; 39(7):1093-8. PubMed ID: 22790045
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer.
    Chacko G; Kota S; Kumar S; Ohri N; Omene C; Ganesan S; Toppmeyer DL; George MA
    Anticancer Drugs; 2023 Apr; 34(4):592-594. PubMed ID: 36846985
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer.
    Brennan M; Gass P; Häberle L; Wang D; Hartmann A; Lux MP; Beckmann MW; Untch M; Fasching PA
    Breast Cancer Res Treat; 2018 Oct; 171(3):747-758. PubMed ID: 29951969
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis.
    Wang H; Zhang S; Yee D; Basu S; Beckwith H; Potter D; Blaes A
    Breast Cancer; 2021 May; 28(3):618-629. PubMed ID: 33387284
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Effect of the administration of zoledronic acid on life expectancy in patients with multiple myeloma with or without renal impairment].
    Morio K; Tsugane M; Mizuki M; Uejima E
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):461-5. PubMed ID: 24743361
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors.
    Ahn SG; Kim SH; Lee HM; Lee SA; Jeong J
    J Breast Cancer; 2014 Dec; 17(4):350-5. PubMed ID: 25548583
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models.
    Janke LJ; Kim J; Payton MA; Jenkins DA; Cai X; Finch ER; Liu Y; Relling MV; Karol SE
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29183. PubMed ID: 34121318
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Combination Therapy with Zoledronic Acid and Parathyroid Hormone Improves Bone Architecture and Strength following a Clinically-Relevant Dose of Stereotactic Radiation Therapy for the Local Treatment of Canine Osteosarcoma in Athymic Rats.
    Curtis RC; Custis JT; Ehrhart NP; Ehrhart EJ; Condon KW; Gookin SE; Donahue SW
    PLoS One; 2016; 11(6):e0158005. PubMed ID: 27332712
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Safety of Inpatient Zoledronic Acid in the Immediate Postfracture Setting.
    Fan W; Leder BZ; Mannstadt M; Ly TV; Franco-Garcia E; Bolster MB
    J Clin Endocrinol Metab; 2023 Oct; 108(11):e1282-e1288. PubMed ID: 37227016
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Treatment of hypertrophic osteoarthropathy in the case of pulmonary metastasis secondary-to-nasopharyngeal carcinoma with zoledronic acid: an enlightening experience.
    Sonthalia N; Mukherjee K; Saha A; Talukdar A
    BMJ Case Rep; 2012 Nov; 2012():. PubMed ID: 23148395
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation.
    Pelizzari G; Gerratana L; Basile D; Fanotto V; Bartoletti M; Liguori A; Fontanella C; Spazzapan S; Puglisi F
    Cancer Treat Rev; 2019 Jan; 72():7-14. PubMed ID: 30414986
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Zoledronic Acid for the Treatment of Children With Refractory Central Giant Cell Granuloma.
    Chien MC; Mascarenhas L; Hammoudeh JA; Venkatramani R
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):e399-401. PubMed ID: 26056788
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis.
    Lorange JP; Ramirez Garcia Luna J; Grou-Boileau F; Rosenzweig D; Weber MH; Akoury E
    J Bone Oncol; 2023 Apr; 39():100470. PubMed ID: 36860585
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Use of zoledronic acid in antiosteoporosis treatment is associated with a decreased blood lipid level in postmenopausal women with osteoporosis: a cohort study in China.
    Luo W; Zhang J; Xu L; Zhou Y; Xu D; Lv Q; Xiao Y; Yang Q
    Postgrad Med; 2022 May; 134(4):406-412. PubMed ID: 35264059
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies.
    Liu Y; Zhao S; Zhang Y; Onwuka JU; Zhang Q; Liu X
    Aging (Albany NY); 2021 Aug; 13(15):19835-19866. PubMed ID: 34375305
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid.
    Yanae M; Fujimoto S; Tane K; Tanioka M; Fujiwara K; Tsubaki M; Yamazoe Y; Morishima Y; Chiba Y; Takao S; Komoike Y; Tsurutani J; Nakagawa K; Nishida S
    J Bone Oncol; 2017 Sep; 8():18-22. PubMed ID: 28884071
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?
    Earl H; Provenzano E; Abraham J; Dunn J; Vallier AL; Gounaris I; Hiller L
    BMC Med; 2015 Sep; 13():234. PubMed ID: 26391216
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Current approaches for neoadjuvant chemotherapy in breast cancer.
    Connolly RM; Stearns V
    Eur J Pharmacol; 2013 Oct; 717(1-3):58-66. PubMed ID: 23545358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.